Your browser doesn't support javascript.
loading
Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies.
Martin, Paul; Gillen, Michael; Millson, David; Oliver, Stuart; Brealey, Clive; Surry, Dominic; Sweeny, David; Lau, David; Leese, Philip.
Afiliación
  • Martin P; AstraZeneca, Macclesfield, UK.
  • Gillen M; AstraZeneca, Wilmington, DE, USA.
  • Millson D; Former-AstraZeneca, Macclesfield, UK.
  • Oliver S; AstraZeneca, Macclesfield, UK.
  • Brealey C; Former-AstraZeneca, Macclesfield, UK.
  • Surry D; Former-AstraZeneca, Macclesfield, UK.
  • Sweeny D; Rigel Pharmaceuticals, Inc, South San Francisco, CA, USA.
  • Lau D; Rigel Pharmaceuticals, Inc, South San Francisco, CA, USA.
  • Leese P; Quintiles Phase I Unit, Overland Park, KS, USA.
Clin Pharmacol Drug Dev ; 5(3): 170-9, 2016 May.
Article en En | MEDLINE | ID: mdl-27163495
Fostamatinib is a prodrug that undergoes gastrointestinal tract dephosphorylation to form the active metabolite, R406. Here we report its cytochrome P450-inducing potential. In vitro, R406 3 and 10 µM induced CYP2C8 to levels representing 53% and 75%, respectively, of the level achieved by the positive control, rifampicin. Induction of other enzymes was minor. The effect of fostamatinib (100 mg twice daily) on the pharmacokinetics of a single oral 30-mg dose of the CYP2C8 substrate pioglitazone and its metabolite, hydroxy pioglitazone, was then investigated (open-label, nonrandomized, 2-period phase I study [n = 15]). Coadministration of fostamatinib and pioglitazone (vs pioglitazone alone) was associated with lower mean maximum plasma concentration values for pioglitazone (geometric least-squares mean ratio, 82.8; 90% confidence interval, 64.2-106.8) and hydroxy pioglitazone (90.9; 78.6-105.1), an increase in pioglitazone AUC (117.8; 108.4-128.0), a decrease in hydroxy pioglitazone AUC(0-t) (89.7; 78.9-101.9), and an increase in pioglitazone geometric mean t1/2λz (9.4-12.8 hours). No tolerability concerns were identified upon coadministration. These data suggest that although clinical significance has not been formally evaluated, fostamatinib is unlikely to have a clinically significant effect on the pharmacokinetics of pioglitazone (which may be extrapolated to other CYP2C8 substrates). However, vigilance is advised should these agents be prescribed together.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazinas / Piridinas / Tiazolidinedionas / Citocromo P-450 CYP2C8 / Inductores de las Enzimas del Citocromo P-450 Tipo de estudio: Prognostic_studies Límite: Adult / Humans / Male / Middle aged Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oxazinas / Piridinas / Tiazolidinedionas / Citocromo P-450 CYP2C8 / Inductores de las Enzimas del Citocromo P-450 Tipo de estudio: Prognostic_studies Límite: Adult / Humans / Male / Middle aged Idioma: En Revista: Clin Pharmacol Drug Dev Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos